In Vivo CAR-T Cell Engineering: Translating Vector Pharmacology into Therapeutic Performance
In Vivo CAR-T cell engineering delivers chimeric antigen receptor (CAR) molecules transgenes directly to endogenous T cells using lentiviral vectors or targeted lipid nanoparticles, bypassing the manufacturing processes of ex vivo cellular therapies. Lentiviral vectors provide integration-based expression for sustained...